Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL621663 | 0.79 | PDE10A (0.39) | NNMTSIRT2SIRT1TDP1POLB | |
| SCHEMBL22773868 | 0.77 | GRM5 (0.34) | GRM5 | |
| SCHEMBL19211801 | 0.75 | GRM5 (0.53) | GRM5POLBCYP1A2KMT2AALDH1A1 | |
| SCHEMBL29595780 | 0.75 | GRM5 (0.53) | GRM5POLBCYP1A2KMT2AALDH1A1 | |
| SCHEMBL15431202 | 0.73 | GRM5 (0.34) | SIRT2GRM5 | |
| SCHEMBL16729351 | 0.71 | TXNRD1 (0.51) | RAB9AMAPK1 | |
| SCHEMBL126903 | 0.71 | NNMT (0.41) | NNMTSIRT2SIRT1TDP1POLB | |
| SCHEMBL29424844 | 0.71 | NNMT (0.41) | NNMTSIRT2SIRT1TDP1POLB | |
| Hydrochloric Acid SCHEMBL3736737 | 0.70 | NNMT (0.40) | NNMTSIRT2SIRT1TDP1POLB | |
| SCHEMBL29743795 | 0.70 | NNMT (0.53) | NNMTSIRT2SIRT1TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958873-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20220298181-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-09-22 | — | — | US | disclosed |
| US-11242361-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242361-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200308198-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
| US-9850262-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850262-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
| WO-2015073528-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | NNMT 2731/4885SIRT2 1089/4885SIRT1 648/4885 |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | NNMT 2731/4885SIRT2 1089/4885SIRT1 648/4885 |
| US-20220298181-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | NNMT 2731/4885SIRT2 1089/4885SIRT1 648/4885 |
| US-11242361-B2 | Proteasome activity enhancing compounds | PSMG3, PSMB1, PSMC1 | NNMT 2731/4885SIRT2 1089/4885SIRT1 648/4885 |
| US-20200308198-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | NNMT 2731/4885SIRT2 1089/4885SIRT1 648/4885 |
| US-11958873-B2 | Proteasome activity enhancing compounds | PSMG3, PSMB1, PSMC1 | NNMT 2731/4885SIRT2 1089/4885SIRT1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.